|
|
地舒单抗对比唑来膦酸治疗前列腺癌骨转移
|
Abstract:
目的：分析地舒单抗对比唑来膦酸治疗前列腺癌骨转移的临床疗效以及不良反应。方法：收集2020年8月至2022年1月期间，在青岛大学附属中心医院、青岛大学附属医院、青岛市立医院治疗的前列腺癌骨转移患者病历资料，按治疗药物分为地舒单抗组和唑来膦酸组，对两组患者治疗前及治疗12周后的骨痛加剧次数、骨痛加重时间、中重度骨痛出现时间、血清碱性磷酸酶(ALP)、不良反应进行评估分析。结果：经两组药物治疗12周后，地舒单抗组的骨痛加剧次数、血清ALP水平明显小于唑来膦酸组。地舒单抗组较唑来膦酸组延缓中重度骨痛发生1.6月，延缓骨痛加重时间3.3个月。两组治疗相关不良反应多为1~2级，安全性整体可控。结论：地舒单抗较唑来膦酸在治疗前列腺癌骨转移可取得更好的临床疗效，安全性整体可控。
Objective: To analyze the clinical efficacy and adverse reactions of denosumab and zoledronic acid in the treatment of prostate cancer with bone metastases. Method: The medical records of prostate cancer patients with bone metastasis treated in the Affiliated Central Hospital of Qingdao University, the Affiliated Hospital of Qingdao University and Qingdao Municipal Hospital from August 2020 to January 2022 were collected. According to the treatment drugs, the patients were divided into denosumab group and zoledronic acid group. The aggravation times of bone pain, aggravation time of bone pain, occurrence time of moderate and severe bone pain, serum alkaline phosphatase (ALP) and adverse reactions of the two groups were evaluated before treatment and 12 weeks after treatment. Results: After 12 weeks of drug treatment in both groups, the frequency of bone pain intensification and serum ALP level in the disulzumab group were significantly lower than those in the zoledronic acid group. Compared with zoledronic acid group, the occurrence of moderate and severe bone pain was delayed for 1.6 months and the aggravation time of bone pain was delayed for 3.3 months in the disulzumab group. Most of the treatment-related adverse reactions in the two groups were grade 1~2, with overall controllable safety. Conclusions: Denosumab has better clinical efficacy than zoledronic acid in the treatment of bone metastasis of prostate cancer, and the safety is controllable overall.
| [1] | Liu, X., Yu, C., Bi, Y. and Zhang, Z.J. (2019) Trends and Age-Period-Cohort Effect on Incidence and Mortality of Prostate Cancer from 1990 to 2017 in China. Public Health, 172, 70-80. https://doi.org/10.1016/j.puhe.2019.04.016 |
| [2] | Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Sta-tistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660 |
| [3] | 中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组. 前列腺癌骨转移多学科诊疗专家共识(2020版) [J]. 肿瘤防治研究, 2020, 47(7): 479-486. |
| [4] | Zhong, Y., Valderrama, A., Yao, J., Donga, P., Bilir, P. and Neumann, P.J. (2018) Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. Value in Health, 21, 304-309.
https://doi.org/10.1016/j.jval.2017.02.008 |
| [5] | 曾浩, 种铁, 贺大林, 等. 去势抵抗性前列腺癌最新指南解读——暨中国西部专家共识[J]. 现代泌尿外科杂志, 2017, 22(2): 85-94. |
| [6] | Cattrini, C., Castro, E., Lozano, R., et al. (2019) Current Treatment Options for Metastatic Hormone-Sensitive Prostate Cancer. Cancers, 11, Article No. 1355. https://doi.org/10.3390/cancers11091355 |
| [7] | Zheng, R., Zhang, S., Zeng, H., et al. (2022) Cancer Incidence and Mortality in China, 2016. Journal of the National Cancer Center, 2, 1-9. https://doi.org/10.1016/j.jncc.2022.02.002 |
| [8] | Body, J.-J., von Moos, R., Rider, A., et al. (2019) A Real-World Study Assessing the Use of Bone-Targeted Agents and Their Impact on Bone Metastases in Patients with Prostate Can-cer Treated in Clinical Practice in Europe. Journal of Bone Oncology, 14, Article ID: 100212. https://doi.org/10.1016/j.jbo.2018.100212 |
| [9] | Wong, K.W., Ma, W.K., Wong, C.W., et al. (2016) Impact of Skel-etal-Related Events on Survival in Patients with Metastatic Prostate Cancer Prescribed Androgen Deprivation Therapy. Hong Kong Medical Journal, 22, 106-115.
https://doi.org/10.12809/hkmj144449 |
| [10] | Coleman, R., Body, J.J., Aapro, M., Hadji, P. and Herrstedt, J. (2014) Bone Health in Cancer Patients: ESMO Clinical Practice Guidelines. Annals of Oncology, 25, III124-III137. https://doi.org/10.1093/annonc/mdu103 |
| [11] | Coleman, R., Hadji, P., Body, J.J., et al. (2020) Bone Health in Can-cer: ESMO Clinical Practice Guidelines. Annals of Oncology, 31, 1650-1663. https://doi.org/10.1016/j.annonc.2020.07.019 |
| [12] | 中国抗癌协会泌尿男生殖系肿瘤专业委员会. 地舒单抗在前列腺癌骨转移患者中的临床应用规范[J]. 肿瘤综合治疗电子杂志, 2021, 7(3): 17-21. |
| [13] | Boyce, B.F. and Xing, L. (2007) Biology of RANK, RANKL, and Osteoprotegerin. Arthritis Research & Therapy, 9, Article No. S1. https://doi.org/10.1186/ar2165 |
| [14] | Baron, R., Ferrari, S. and Russell, R.G. (2011) Denosumab and Bisphospho-nates: Different Mechanisms of Action and Effects. Bone, 48, 677-692. https://doi.org/10.1016/j.bone.2010.11.020 |
| [15] | de Groot, A.F., Appelman-Dijkstra, N.M., van der Burg, S.H. and Kroep, J.R. (2018) The Anti-Tumor Effect of RANKL Inhibition in Malignant Solid Tumors—A Systematic Review. Cancer Treatment Reviews, 62, 18-28.
https://doi.org/10.1016/j.ctrv.2017.10.010 |
| [16] | Smith, M.R., Saad, F., Coleman, R., et al. (2012) Denosumab and Bone-Metastasis-Free Survival in Men with Castration-Resistant Prostate Cancer: Results of a Phase 3, Randomised, Placebo-Controlled Trial. Lancet, 379, 39-46.
https://doi.org/10.1016/S0140-6736(11)61226-9 |
| [17] | Ahern, E., Smyth, M.J., Dougall, W.C. and Teng, M.W.L. (2018) Roles of the RANKL-RANK Axis in Antitumour Immunity—Implications for Therapy. Nature Reviews Clinical Oncology, 15, 676-693.
https://doi.org/10.1038/s41571-018-0095-y |
| [18] | Gómez-Aleza, C., Nguyen, B., Yoldi, G., et al. (2020) Inhibition of RANK Signaling in Breast Cancer Induces an Anti-Tumor Immune Response Orchestrated by CD8+ T Cells. Nature Communications, 11, Article No. 6335.
https://doi.org/10.1038/s41467-020-20138-8 |
| [19] | Zhang, X. (2019) Interactions between Cancer Cells and Bone Microenvironment Promote Bone Metastasis in Prostate Cancer. Cancer Communications, 39, Article No. 76. https://doi.org/10.1186/s40880-019-0425-1 |
| [20] | Bhowmik, D., Song, X., Intorcia, M., Gray, S. and Shi, N. (2019) Examination of Burden of Skeletal-Related Events in Patients Naive to Denosumab and Intravenous Bisphosphonate Therapy in Bone Metastases from Solid Tumors Population. Current Medical Research and Opinion, 35, 513-523. https://doi.org/10.1080/03007995.2018.1532884 |
| [21] | 中国抗癌协会泌尿男生殖系统肿瘤专业委员会. 前列腺癌骨转移和骨相关疾病临床诊疗专家共识(2021版) [J]. 中华肿瘤杂志, 2021, 43(10): 1016-1026. |
| [22] | 郭卫. 乳腺癌骨转移临床诊疗专家共识[J]. 中国肿瘤临床, 2022, 49(13): 660-669. |
| [23] | Fizazi, K., Carducci, M., Smith, M., et al. (2011) Denosumab versus Zoledronic Acid for Treatment of Bone Metastases in Men with Castration-Resistant Pros-tate Cancer: A Randomised, Double-Blind Study. Lancet, 377, 813-822.
https://doi.org/10.1016/S0140-6736(10)62344-6 |
| [24] | Zhao, H., Han, K.-L., Wang, Z.-Y., et al. (2011) Value of C-Telopeptide-Cross-Linked Type I Collagen, Osteocalcin, Bone-Specific Alkaline Phosphatase and Procollagen Type I N-Terminal Propeptide in the Diagnosis and Prognosis of Bone Metastasis in Patients with Malignant Tumors. Medical Science Monitor, 17, CR626-CR633.
https://doi.org/10.12659/MSM.882047 |
| [25] | Gibiansky, L., Sutjandra, L., Doshi, S., et al. (2012) Population Phar-macokinetic Analysis of Denosumab in Patients with Bone Metastases from Solid Tumours. Clinical Pharmacokinetics, 51, 247-260.
https://doi.org/10.2165/11598090-000000000-00000 |
| [26] | 夏维波, 廖二元, 章振林, 等. 补钙和维生素D对骨骼健康的必要性[J]. 中华骨质疏松和骨矿盐疾病杂志, 2018, 11(1): 1674-2591. |
